UNSPSC 51123906: Propafenone

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C21H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 68IQX3T69U, chemically known as 1-propanone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl- but more generally known as propafenone, which bears US NIH Compound Identifier 4932. European Medicines Agency schedules Propafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10094MIG.

UNSPSC 51123906 Propafenone, a Commodity code, encompasses antiarrhythmic pharmaceutical products that state and local governments procure primarily for emergency medical services and pharmacy benefit programs. State and local buying under this code centers on emergency medications supplied to fire rescue departments and hospital systems, as well as formulary participation through cooperative purchasing alliances and direct-to-manufacturer pharmacy programs. Issuing bodies include municipal fire departments, state health and human services agencies, and multistate cooperative purchasing organizations. The scope of work involves supplying finished pharmaceutical products with specific expiration-date requirements, OSHA-compliant Safety Data Sheets, cGMP and Drug Supply Chain Security Act compliance certification, and warranty provisions covering product defects and expired-material replacement.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, including Labetalol, Epinephrine, Adenosine, and Diltiazem vials, with a firm-bid due date of April 8, 2026 and an estimated contract value of $40,000; the solicitation carries a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for self-insured group health plans and state agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) with a March 26, 2026 response deadline to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers across participating state and local facilities, including Oregon, with contract effectiveness set for July 1, 2026 and vendor pricing weighted at 75 percent of evaluation criteria.